Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
Executive Summary
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
You may also be interested in...
Patient Input Comes Full Circle: Ex-FDAer Gives Feedback To FDA
US agency's April 6 patient-focused drug development meeting on sarcopenia sent two very divergent messages about the status of measuring patient engagement on new drug development: both delivered by an unexpected messenger, former FDAer Ray Lipicky.
CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition
In podcast interview, US FDA’s Center for Drug Evaluation & Research Director Janet Woodcock discusses her plans the Office of New Drugs, including changes to the structure of the office to make reviews better managed and more uniform across divisions. Woodcock says she expects to stay in the interim OND role for most of 2017.
FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?
US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.